tiprankstipranks
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market
Holding NAMS?
Track your performance easily

NewAmsterdam Pharma Company (NAMS) Income Statement

139 Followers

NewAmsterdam Pharma Company Income Statement

Last quarter (Q3 2024), NewAmsterdam Pharma Company's total revenue was $29.11M, an increase of Infinity% from the same quarter last year. In Q3, NewAmsterdam Pharma Company's net income was $-15.88M. See NewAmsterdam Pharma Company’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 31.39M$ 14.09M$ 97.50M$ 0.00$ 0.00
Cost of Revenue
--$ 60.60M--
Gross Profit
$ 31.39M$ 14.09M$ 36.90M--
Operating Expense
$ 108.97M$ 197.06M$ 104.73M$ 1.37M$ 127.66K
Operating Income
$ -77.58M$ -182.97M$ -67.83M$ -1.37M$ -127.66K
Net Non Operating Interest Income Expense
$ 9.31M$ -3.42M$ 11.00K$ 16.16K$ 851.00
Other Income Expense
-$ -5.23M$ 976.00K$ 5.53M$ 168.26K
Pretax Income
$ -55.66M$ -176.91M$ -78.05M$ 4.18M$ 41.45K
Tax Provision
$ -1.00K$ 27.00K---
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -64.58M$ -176.94M$ -78.05M$ 4.18M$ 41.45K
Basic EPS
$ -0.86$ -2.15$ -0.96$ 0.24$ 0.01
Diluted EPS
$ -0.86$ -2.15$ -0.96$ 0.24$ <0.01
Basic Average Shares
$ 207.22M$ 82.16M$ 81.56M$ 17.75M$ 6.60M
Diluted Average Shares
$ 207.22M$ 82.16M$ 81.30M$ 17.75M$ 6.94M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 108.97M$ 197.06M$ 165.33M$ 1.37M$ 127.66K
Net Income From Continuing And Discontinued Operation
$ -54.88M$ -176.94M$ -78.05M$ 4.18M$ 41.45K
Normalized Income
$ -47.46M$ -139.76M-$ 142.61K$ -81.38K
Interest Expense
-----
EBIT
$ -54.88M$ -166.63M$ -78.06M$ -1.37M$ -127.66K
EBITDA
$ -54.84M$ -166.58M$ -77.99M$ -1.37M$ -127.66K
Currency in USD

NewAmsterdam Pharma Company Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis